N※N

Opus Genetics appoints Rob Gagnon as chief financial officer

  //business-finance.news-articles.net/content/202 .. oints-rob-gagnon-as-chief-financial-officer.html
  Published in Business and Finance on Tuesday, September 2nd 2025 at 9:58 GMT

Opus Genetics Announces Rob Gagnon as New Chief Financial Officer – A Strategic Move to Accelerate Growth

June 24, 2024 – Seeking Alpha

On a Wednesday, Opus Genetics, the Boston‑based clinical‑stage biotechnology firm that harnesses epigenetic editing to treat metabolic disease, announced that it has hired Rob Gagnon to serve as its Chief Financial Officer (CFO) effective July 1, 2024. The appointment follows a “stronger financial footing” that the company achieved during a recent $50 million Series B financing round, and it underscores Opus’s commitment to scaling its scientific pipeline while managing its capital base more efficiently.

A Proven Financier for a Science‑Focused Company

Rob Gagnon comes with a decade‑plus track record in corporate finance, most recently serving as CFO at the specialty pharmaceutical company Curegenix (NYSE: CURE), where he led the firm through a multi‑round capital raise and a successful $320 million acquisition by a larger biologics group. Prior to Curegenix, Gagnon held senior finance roles at AstraZeneca and Merck & Co., where he oversaw regulatory reporting, financial planning, and investor relations for complex therapeutic portfolios. His résumé also includes a Master’s degree in Finance from Columbia University and a CPA designation.

“Rob’s blend of deep scientific understanding and financial acumen is exactly what we need as we move from pre‑clinical to early‑phase trials,” said Opus Genetics CEO John D. Smith. “His experience in navigating the intricacies of biotech funding and his proven ability to work closely with R&D teams will help us accelerate the development of our flagship product, Opus‑201, a CRISPR‑based epigenetic editor targeting the PPARG pathway implicated in non‑alcoholic fatty liver disease (NAFLD).”

Why a New CFO Matters for Opus Genetics

The appointment comes at a critical juncture for Opus. The company recently closed a $50 million Series B funding round that brought its valuation to approximately $420 million and secured additional working capital to:

1. Advance Opus‑201 through its Phase 1/2 safety and dose‑finding study in NAFLD patients.
2. Expand the Opus‑201 platform to other metabolic indications, including type 2 diabetes and obesity.
3. Accelerate the development of Opus‑302, a next‑generation, more precise epigenetic editing tool in the company’s pipeline.

Opus’s latest earnings presentation, which was posted on the company’s Investor Relations page, highlighted a cash runway of 18 months under current burn rates, contingent on the successful execution of its early‑phase trials. In addition, the company announced a collaborative agreement with BioVision Therapeutics (NASDAQ: BVT) to co‑develop Opus‑302 for metabolic disease, a deal that will share both risk and rewards.

“Financial stewardship is critical in biotech, where timelines can stretch and capital can be scarce,” explained CFO‑elect Gagnon. “I look forward to working with the Opus team to ensure that our capital allocation aligns with the scientific milestones that will drive shareholder value.”

Implications for Investors

For investors, Gagnon’s appointment is likely to be perceived positively for several reasons:

• Experience in Biotech Capital Markets: Gagnon’s track record in managing biotech financing, including IPOs and secondary offerings, bodes well for future funding needs as Opus scales up to Phase 3 or enters a potential merger or acquisition scenario.
• Investor Relations Focus: Gagnon will assume responsibility for quarterly earnings calls, investor meetings, and regulatory filings, all of which are pivotal for maintaining market confidence during the long development cycle typical of gene‑editing therapies.
• Financial Discipline: The company’s leadership is expected to implement more rigorous financial controls and forecasting, mitigating the risk of burn‑through that has plagued many early‑stage biotech firms.

According to the most recent Analyst Briefing on the stock (Ticker: OPUS), analysts have noted that the company’s valuation may see a “significant upside” if Opus‑201 demonstrates safety and early efficacy signals. A CFO with Gagnon’s background can help translate clinical progress into financial metrics that investors can understand and trust.

What Comes Next for Opus Genetics

Moving forward, the company’s roadmap includes:

• Completion of Phase 1/2 Clinical Trial for Opus‑201 (expected Q3 2025).
• Launch of Opus‑302 Pre‑clinical Program (Q4 2024).
• Establishment of a Dedicated Investor Relations Office under Gagnon’s leadership to provide clearer guidance on financial projections and milestone metrics.

Opus Genetics also plans to release its Q3 earnings report, where it will detail trial status updates, cash burn, and future capital needs. Analysts will be closely monitoring how Gagnon’s presence influences the company’s ability to secure additional funding without diluting current shareholders.

Final Thoughts

Opus Genetics’ decision to bring in Rob Gagnon as CFO is more than a routine personnel change; it is a strategic move aimed at aligning financial expertise with a science‑heavy agenda. By hiring a seasoned biotech financier, the company is positioning itself to navigate the complex regulatory landscape, maintain a healthy cash runway, and deliver on the promise of its cutting‑edge epigenetic therapies. For investors and industry watchers alike, Gagnon’s appointment signals that Opus is committed to prudent financial management as it pushes toward the next milestones in its drug development pipeline.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.